Analyst Price Targets — HRTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 9, 2025 10:08 am | Brandon Folkes | H.C. Wainwright | $6.00 | $2.12 | TheFly | Heron Therapeutics initiated with a Buy at H.C. Wainwright |
| May 16, 2024 2:04 pm | Carl Byrnes | Northland Securities | $9.00 | $3.22 | StreetInsider | Northland Reiterates Outperform Rating on Heron Therapeutics (HRTX) |
| March 13, 2024 7:08 am | Serge Belanger | Needham | $5.00 | $3.01 | StreetInsider | Heron Therapeutics (HRTX) PT Raised to $5 at Needham to reflect strong sales trends |
Latest News for HRTX
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC…
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HRTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.